Evidence for persistence of the SHIV reservoir early after MHC haploidentical hematopoietic stem cell transplantation

Allogeneic transplantation (allo-HCT) has led to the cure of HIV in one individual, raising the question of whether transplantation can eradicate the HIV reservoir. To test this, we here present a model of allo-HCT in SHIV-infected, cART-suppressed nonhuman primates. We infect rhesus macaques with S...

Full description

Saved in:
Bibliographic Details
Published inNature communications Vol. 9; no. 1; pp. 4438 - 15
Main Authors Colonna, Lucrezia, Peterson, Christopher W., Schell, John B., Carlson, Judith M., Tkachev, Victor, Brown, Melanie, Yu, Alison, Reddy, Sowmya, Obenza, Willi M., Nelson, Veronica, Polacino, Patricia S., Mack, Heather, Hu, Shiu-Lok, Zeleski, Katie, Hoffman, Michelle, Olvera, Joe, Furlan, Scott N., Zheng, Hengqi, Taraseviciute, Agne, Hunt, Daniel J., Betz, Kayla, Lane, Jennifer F., Vogel, Keith, Hotchkiss, Charlotte E., Moats, Cassie, Baldessari, Audrey, Murnane, Robert D., English, Christopher, Astley, Cliff A., Wangari, Solomon, Agricola, Brian, Ahrens, Joel, Iwayama, Naoto, May, Andrew, Stensland, Laurence, Huang, Meei-Li W., Jerome, Keith R., Kiem, Hans-Peter, Kean, Leslie S.
Format Journal Article
LanguageEnglish
Published London Nature Publishing Group UK 25.10.2018
Nature Publishing Group
Nature Portfolio
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Allogeneic transplantation (allo-HCT) has led to the cure of HIV in one individual, raising the question of whether transplantation can eradicate the HIV reservoir. To test this, we here present a model of allo-HCT in SHIV-infected, cART-suppressed nonhuman primates. We infect rhesus macaques with SHIV-1157ipd3N4, suppress them with cART, then transplant them using MHC-haploidentical allogeneic donors during continuous cART. Transplant results in ~100% myeloid donor chimerism, and up to 100% T-cell chimerism. Between 9 and 47 days post-transplant, terminal analysis shows that while cell-associated SHIV DNA levels are reduced in the blood and in lymphoid organs post-transplant, the SHIV reservoir persists in multiple organs, including the brain. Sorting of donor-vs.-recipient cells reveals that this reservoir resides in recipient cells. Moreover, tetramer analysis indicates a lack of virus-specific donor immunity post-transplant during continuous cART. These results suggest that early post-transplant, allo-HCT is insufficient for recipient reservoir eradication despite high-level donor chimerism and GVHD. Allogeneic hematopoietic cell transplantation (allo-HCT) has led to the cure of HIV in one individual, but the underlying mechanisms are unclear. Here, the authors present a model of allo-HCT in SHIV-infected nonhuman primates and show that the SHIV reservoir persists in multiple tissues early after transplantation.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:2041-1723
2041-1723
DOI:10.1038/s41467-018-06736-7